UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Journal Article
  • Authors:
    Wong AMS, Rahim AA, Waddington SN, Cooper JD
  • Publication date:
    12/2010
  • Pagination:
    1484, 1488
  • Journal:
    Biochem Soc Trans
  • Volume:
    38
  • Issue:
    6
  • Status:
    Published
  • Country:
    England
  • PII:
    BST0381484
  • Language:
    eng
  • Keywords:
    Animals, Child, Endocytosis, Enzyme Replacement Therapy, Genetic Therapy, Humans, Lysosomes, Membrane Proteins, Mice, Molecular Chaperones, Mutation, Neuronal Ceroid-Lipofuscinoses, Receptor, IGF Type 2, Stem Cell Transplantation
Abstract
The NCLs (neuronal ceroid lipofuscinoses) are the most common inherited paediatric neurodegenerative disorder. Although genetically distinct, NCLs can be broadly divided into two categories: one in which the mutation results in a defect in a transmembrane protein, and the other where the defect lies in a soluble lysosomal enzyme. A number of therapeutic approaches are applicable to the soluble lysosomal forms of NCL based on the phenomenon of cross-correction, whereby the ubiquitously expressed mannose 6-phosphate/IGF (insulin-like growth factor) II receptor provides an avenue for endocytosis, trafficking and lysosomal processing of extracellularly delivered enzyme. The present review discusses therapeutic utilization of cross-correction by enzyme-replacement therapy, gene therapy and stem cell therapy for the NCLs, along with an overview of the recent progress in translating these treatments into the clinic.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Pharmacology
Author
Maternal & Fetal Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by